		·
1 2 3 4 5 6 7 8 9		RE THE PHARMACY
10	DEPARTMENT OF C	CONSUMER AFFAIRS CALIFORNIA
11 12	In the Matter of the Accusation Against:	Case No. 5845
12	WELLNESS PHARMACY, INC. DBA WELLNESS PHARMACY	
14	3401 Independence Dr., #231 Birmingham, AL 35209	FIRST AMENDED ACCUSATION
15	Non-Resident Pharmacy Permit No. NRP 549	
16	110. INKE 549	
17	Non-Resident Sterile Compounding Permit No. NSC 99103	
18	Respondent.	
19		
20		
21	Complainant alleges:	
22	PAR	TIES
23	1. Virginia Herold (Complainant) bring	s this First Amended Accusation solely in her
24	official capacity as the Executive Officer of the E	Board of Pharmacy (Board), Department of
25	Consumer Affairs.	
26	2. On or about September 2, 2003, the I	Board issued Non-Resident Pharmacy Permit
27	Number NRP 549 to Wellness Pharmacy, Inc. db	a Wellness Pharmacy (Respondent). The permit
28	will expire on September 1, 2016, unless renewed	1.
	. 1	
	(WELLNESS PHARMACY, INC. DBA WELLI	NESS PHARMACY) FIRST AMENDED ACCUSATION

.

1	3. On or about December 9, 2003, the Board issued Non-Resident Sterile Compoundin	g
2	Permit Number NSC 99103 to the Pharmacy. The permit will expire on September 1, 2016,	
3	unless renewed.	
4	4. Both the Non-Resident Pharmacy Permit and the Non-Resident Sterile Compounding	g
5	Permit were in full force and effect at all times relevant to the charges brought herein.	
6	JURISDICTION	
7	(California Business and Professions Code)	
8	5. This First Amended Accusation is brought before the Board under the authority of	
9	the following laws. All code references are to the Business and Professions Code unless	
10	otherwise noted.	
11	6. Section 4300 of the Code states, in pertinent part:	
12	(a) Every license issued may be suspended or revoked.	
13	(b) The board shall discipline the holder of any license issued by the board,	
14	whose default has been entered or whose case has been heard by the board and found guilty, by any of the following methods:	
15	(1) Suspending judgment.	
16	(2) Placing him or her upon probation.	
17	(3) Suspending his or her right to practice for a period not exceeding one year.	
18	(4) Revoking his or her license.	
19	(5) Taking any other action in relation to disciplining him or her as the	
20	board in its discretion may deem proper.	
21		
22	7. Section 4300.1 of the Code states:	
23	The expiration, cancellation, forfeiture, or suspension of a board-issued license by operation of law or by order or decision of the board or a court of law, the	
24	placement of a license on a retired status, or the voluntary surrender of a license by a licensee shall not deprive the board of jurisdiction to commence or proceed with	
25	any investigation of, or action or disciplinary proceeding against, the licensee or to render a decision suspending or revoking the license.	
26	 Section 4301 of the Code states in pertinent part: 	
27	The board shall take action against any holder of a license who is guilty of	
28	unprofessional conduct or whose license has been procured by fraud or	
	2	
	(WELLNESS PHARMACY, INC. DBA WELLNESS PHARMACY) FIRST AMENDED ACCUSATION	JΤ

LAND.

⁽WELLNESS PHARMACY, INC. DBA WELLNESS PHARMACY) FIRST AMENDED ACCUSATION

misrepresentation or issued by mistake. Unprofessional conduct shall include, but is 1 not limited to, any of the following: 2 (i) The violation of any of the statutes of this state, or any other state, or of the 3 United States regulating controlled substances or dangerous drugs. 4 5 6 (o) Violating or attempting to violate, directly or indirectly, or assisting in or abetting the violation of or conspiring to violate any provision or term of this 7 chapter or of the applicable federal and state laws and regulations governing pharmacy, including regulations established by the board or by any other state or federal regulatory agency. 1 8 9 9. Section 4342 of the Code states in pertinent part: 10 11 (a) The board may institute any action or actions as may be provided by law and that, in its discretion, are necessary, to prevent the sale of pharmaceutical 12 preparations and drugs that do not conform to the standard and tests as to quality and strength, provided in the latest edition of the United States Pharmacopoeia or the National Formulary, or that violate any provision of the Sherman Food, Drug, and 13 Cosmetic Law. 14 15 16 (California Code of Regulations) 10. California Code of Regulations, title 16, section 1714, states in pertinent part: 17 18 (b) Each pharmacy licensed by the board shall maintain its facilities, space, 19 fixtures, and equipment so that drugs are safely and properly prepared, maintained, secured and distributed. The pharmacy shall be of sufficient size and unobstructed 20area to accommodate the safe practice of pharmacy. 21 (c) The pharmacy and fixtures and equipment shall be maintained in a clean and orderly condition. The pharmacy shall be dry, well-ventilated, free from rodents 22 and insects, and properly lighted. The pharmacy shall be equipped with a sink with hot and cold running water for pharmaceutical purposes. 23 24 11. California Code of Regulations, title 16, section 1735.2, states in pertinent part: 25 26 (d) A drug product shall not be compounded until the pharmacy has first 27 prepared a written master formula record that includes at least the following elements: 28 3

1	(2) Equipment to be used.
2	
3	12. California Code of Regulations, title 16, section 1735.6, states in pertinent part:
4	••••
5	(b) Any equipment used to compound drug products shall be stored, used, and maintained in accordance with manufacturer's specifications.
6	• • • •
7	13. California Code of Regulations, title 16, section 1751.4, states in pertinent part:
. 8	
9	(c) All equipment used in the designation area or cleanroom must be made of a material that can easily be cleaned and disinfected.
10	••••
11	14. California Code of Regulations, title 16, section 1751.7, states in pertinent part:
12	
13	(b) Each individual involved in the preparation of sterile injectable products must first successfully complete a validation process The validation process shall be corrived out in the same memory as normal and duration
14	be carried out in the same manner as normal production, except that an appropriate microbiological growth medium is used in place of the actual product used during sterile preparation. The validation process shall be representative of all types of
15 16	manipulations, products and batch sizes the individual is expected to prepare. The same personnel, procedures, equipment, and materials must be involved. Completed medium samples must be incubated
17	••••
18	COST RECOVERY
19	15. Business and Professions Code section 125.3 provides, in pertinent part, that a board
20	may request the administrative law judge to direct a licentiate found to have committed a
21	violation or violations of the licensing act to pay a sum not to exceed the reasonable costs of the
22	investigation and enforcement of the case.
23	BACKGROUND
24	16. On August 20, 2014, the Board conducted an inspection at Respondent's facility
25	located in Birmingham, Alabama. Respondent is an out-of-state pharmacy licensed with both a
26	non-resident pharmacy permit and a non-resident sterile compounding permit.
27	///
28	
	4
	(WELLNESS PHARMACY, INC. DBA WELLNESS PHARMACY) FIRST AMENDED ACCUSATION

1 ||

2

3

4

5

6

111

17. The inspection was conducted by Board inspector P.P.

18. After arriving at Respondent's facility, Pharmacist-In-Charge M.D., assisted
Inspector P.P. with the investigation by escorting Inspector P.P. through the facility. Upon
reaching the compounding area of the pharmacy, Inspector P.P. entered the compounding area for
the purpose of inspection.

19. Upon entering the compounding area, where Respondent conducted high risk sterile 7 drug compounding, Inspector P.P. observed three laminar flow hoods.¹ Inspector P.P. observed 8 Hood #1 to be in good operating condition. Inspector P.P. observed Hood #2 to have cracked 9 glass and rust or some other substance or debris inside the metal track holding the glass. 10Respondent did not conduct surface testing to determine whether the rust or other substance or 11 debris was causing any problems with unwanted bacterial or fungal growth. Inspector P.P. 12 observed Hood #3 to have a broken light, an abundance of rust throughout the hood, and a dark 13 and slimy appearing substance inside the grates of the hood. 14

20. While inside the compounding area, Inspector P.P. observed a chair in front of Hood
#1 with a damaged seatback. The condition of the chair was such that the inner cushioning of the
seatback protruded from the chair.

18 21. When asked, it was determined that Respondent maintained no records of the
19 materials compounded under each hood. Thus, if a problem with contamination occurred, it
20 would be difficult, if not impossible, to narrow down the source of the contamination. When the
21 master formula for compounded materials was reviewed, it was determined that Respondent's
22 master formulas failed to identify the equipment used during and for the compounding.

23 22. Process validation is when an individual demonstrates that he or she is familiar with
24 the techniques to compound or mix medication, aseptically. Process validation is required
25 annually unless the pharmacist completes compounding of medications that are classified as

26

27

28

¹ A laminar flow hood is an enclosed work bench where air is drawn through a filter and blown over the work area in a manner designed to prevent contamination of the materials being prepared within the hood.

"high risk," in which case process validation is required every six months according to United 1 States Pharmacopeia <797>. Respondent represented that Alabama, the state in which 2 Respondent operates, complies with United States Pharmacopeia <797> and therefore. 3 Respondent was required to complete process validation every six months. Respondent's records 4 indicated that Respondent regularly compounded medication in batches of up to 900ml at a time. 5 Thereafter, the compounded medication would be manipulated or divided into smaller dispensing 6 sizes for distribution. The validation process records indicated that Respondent's compounding 7 staff regularly used a smaller quantity than what was actually compounded for production. The 8 records of process validation showed that Respondent's compounding staff conducted process 9 validation with only approximately 85ml when the intended production batch of medication 10would be 700ml. 11 12 FIRST CAUSE FOR DISCIPLINE 13 (Failure to Record Equipment Used in Compounding) Respondent's Non-Resident Pharmacy Permit and Non-Resident Sterile 14 23. 15 Compounding Permit are subject to disciplinary action under California Code of Regulations, title 16 16, section 1735.2, subdivision (d)(2) in that Respondent did not specify equipment used in 17 compounding as detailed above in Paragraph 21. 18 SECOND CAUSE FOR DISCIPLINE (Failure to Maintain Equipment in Good Working Condition) 19 Respondent's Non-Resident Pharmacy Permit and Non-Resident Sterile 24. $2\dot{0}$ Compounding Permit are subject to disciplinary action under California Code of Regulations, title 21 16, sections 1714 and 1735.6, subdivision (d)(2) in that Respondent conducted compounding of 22 high risk sterile drug compounds in damaged and dirty laminar flow hoods as detailed above in 23 Paragraph 19. 24 THIRD CAUSE FOR DISCIPLINE 25 (Failure to Use Easily Cleaned and Disinfected 26**Equipment in Designated Cleanroom**) 25. Respondent's Non-Resident Pharmacy Permit and Non-Resident Sterile 27 28 Compounding Permit are subject to disciplinary action under California Code of Regulations, title 6

(WELLNESS PHARMACY, INC. DBA WELLNESS PHARMACY) FIRST AMENDED ACCUSATION

16, section 1751.4, subdivision (c) in that Respondent utilized a chair in the sterile compounding room that was in such a condition that it could not be easily cleaned and disinfected as detailed above in Paragraph 20.

FOURTH CAUSE FOR DISCIPLINE (Failure to Process Validation Manipulations in Volumes Consistent with Amounts Anticipated to be Prepared)

6 26. Respondent's Non-Resident Pharmacy Permit and Non-Resident Sterile
7 Compounding Permit are subject to disciplinary action under California Code of Regulations, title
8 16, section 1751.7 in that Respondent conducted process validation in amounts that were not
9 indicative of the high volume batches prepared by the pharmacy as detailed above in Paragraph
10 22.

DISCIPLINARY CONSIDERATIONS

27. To determine the degree of discipline to be assessed against Respondent Wellness 12 Pharmacy, if any, Complainant alleges that between September 22, 2014 and September 30, 13 2014, the United States Food and Drug Administration (FDA) completed an inspection at 14 Respondent's facility and issued a report. The FDA inspection noted multiple areas of deficiency 15 including, but not limited to, failure to complete endotoxin testing and potency testing on 100% 16 of products, failure to routinely calibrate thermometers, hygrometers, and pressure gauges, failure 17 to produce stability data for purported sterile drug products, and stability data accounting for 18 expiration dates assigned to drug products. 19

20

21

22

1

2

3

4

5

11

<u>PRAYER</u>

WHEREFORE, Complainant requests that a hearing be held on the matters herein alleged, and that following the hearing, the Board of Pharmacy issue a decision:

Revoking or suspending Non-Resident Pharmacy Permit Number NRP 549, issued to
 Wellness Pharmacy, Inc. dba Wellness Pharmacy

2. Revoking or suspending Non-Resident Sterile Compounding Permit Number NSC
26 99103, issued to Wellness Pharmacy, Inc. dba Wellness Pharmacy;

27 || ///

28 ///

7

/// Ordering Wellness Pharmacy, Inc. dba Wellness Pharmacy to pay the Board of 3. Pharmacy the reasonable costs of the investigation and enforcement of this case, pursuant to Business and Professions Code section 125.3; Taking such other and further action as deemed necessary and proper. 4. 1/12/17 DATED: VIRGINIA HEROLD Executive Officer Board of Pharmacy Department of Consumer Affairs State of California Complainant SA2016102068 12318441.doc (WELLNESS PHARMACY, INC. DBA WELLNESS PHARMACY) FIRST AMENDED ACCUSATION

1	KAMALA D. HARRIS	
2	Attorney General of California KENT D. HARRIS	•
3	Supervising Deputy Attorney General STANTON W. LEE	
4	Deputy Attorney General State Bar No. 203563	
5	1300 I Street, Suite 125 P.O. Box 944255	• •
6	Sacramento, CA 94244-2550 Telephone: (916) 445-9921	
7	Facsimile: (916) 324-5567 E-mail: Stanton.Lee@doj.ca.gov	
8	Attorneys for Complainant	
9	BEFOR BOARD OF J	PHARMACY
10	DEPARTMENT OF C STATE OF C	CONSUMER AFFAIRS CALIFORNIA
11		
12	In the Matter of the Accusation Against:	Case No. 5845
13	WELLNESS PHARMACY, INC. DBA WELLNESS PHARMACY	
14	3401 Independence Dr., #231 Birmingham, AL 35209	ACCUSATION
15	Non-Resident Pharmacy Permit	
16	No. NRP 549	
17	Non-Resident Sterile Compounding Permit	
18	No. NSC 99103 Respondent.	
19	Respondent.	
20		
21	Complainant alleges:	
22	PAR	RTIES
23	1. Virginia Herold (Complainant) bring	gs this Accusation solely in her official capacity
24	as the Executive Officer of the Board of Pharma	cy (Board), Department of Consumer Affairs.
25	2. On or about September 2, 2003, the	Board issued Non-Resident Pharmacy Permit
26	Number NRP 549 to Wellness Pharmacy, Inc. d	ba Wellness Pharmacy (Pharmacy). The permit
27	will expire on September 1, 2016, unless renewe	ed.
28	///	
		1
	(WELLNESS PHARMAC	Y, INC. DBA WELLNESS PHARMACY) ACCUSATION

-

	:
1	3. On or about December 9, 2003, the Board issued Non-Resident Sterile Compounding
2	Permit Number NSC 99103 to the Pharmacy. The permit will expire on September 1, 2016,
3	unless renewed.
4	4. Both the Non-Resident Pharmacy Permit and the Non-Resident Sterile Compounding
5	Permit were in full force and effect at all times relevant to the charges brought herein.
6	JURISDICTION
7	(California Business and Professions Code)
8	5. This Accusation is brought before the Board under the authority of the following
9	laws. All code references are to the Business and Professions Code unless otherwise noted.
10	6. Section 4300 of the Code states, in pertinent part:
11	(a) Every license issued may be suspended or revoked.
12	(b) The board shall discipline the holder of any license issued by the board,
13	whose default has been entered or whose case has been heard by the board and found guilty, by any of the following methods:
14	(1) Suspending judgment.
15	(2) Placing him or her upon probation.
16	(3) Suspending his or her right to practice for a period not exceeding
17	one year.
18	(4) Revoking his or her license.
19	(5) Taking any other action in relation to disciplining him or her as the board in its discretion may deem proper.
20	••••
21	7. Section 4300.1 of the Code states:
22	The expiration, cancellation, forfeiture, or suspension of a board-issued license by operation of law or by order or decision of the board or a court of law, the
23	placement of a license on a retired status, or the voluntary surrender of a license by a license shall not deprive the board of jurisdiction to commence or proceed with
24	any investigation of, or action or disciplinary proceeding against, the licensee or to render a decision suspending or revoking the license.
25	8. Section 4301 of the Code states in pertinent part:
26	The board shall take action against any holder of a license who is guilty of
27	unprofessional conduct or whose license has been procured by fraud or misrepresentation or issued by mistake. Unprofessional conduct shall include, but is
28	not limited to, any of the following:
	2
	(WELLNESS PHARMACY, INC. DBA WELLNESS PHARMACY) ACCUSATION

1		
2	(j) The violation of any of the statutes of this state, or any other state, or of the	
3	United States regulating controlled substances or dangerous drugs.	
4		
5	(o) Violating or attempting to violate, directly or indirectly, or assisting in	
6	or abetting the violation of or conspiring to violate any provision or term of this chapter or of the applicable federal and state laws and regulations governing	Ì
7	pharmacy, including regulations established by the board or by any other state or federal regulatory agency.	
8	• • • •	
9	9. Section 4342 of the Code states in pertinent part:	
10	(a) The board may institute any action or actions as may be provided by law	
11	and that, in its discretion, are necessary, to prevent the sale of pharmaceutical preparations and drugs that do not conform to the standard and tests as to quality and	
12	strength, provided in the latest edition of the United States Pharmacopoeia or the National Formulary, or that violate any provision of the Sherman Food, Drug, and	
13	Cosmetic Law.	
14	••••	
15	(California Code of Regulations)	
16	10. California Code of Regulations, title 16, section 1714, states in pertinent part:	
17		
18	(b) Each pharmacy licensed by the board shall maintain its facilities, space, fixtures, and equipment so that drugs are safely and properly prepared, maintained, secured and distributed. The pharmacy shall be of sufficient size and unobstructed	
19	area to accommodate the safe practice of pharmacy.	
20 21	(c) The pharmacy and fixtures and equipment shall be maintained in a clean and orderly condition. The pharmacy shall be dry, well-ventilated, free from rodents and insects, and properly lighted. The pharmacy shall be equipped with a sink with	
21	hot and cold running water for pharmaceutical purposes.	
22		
23 24	11. California Code of Regulations, title 16, section 1735.2, states in pertinent part:	
25		
26	(d) A drug product shall not be compounded until the pharmacy has first prepared a written master formula record that includes at least the following elements:	
27		
28	(2) Equipment to be used.	
	3	
	(WELLNESS PHARMACY, INC. DBA WELLNESS PHARMACY) ACCUSATION	1

н	
1	
2	12. California Code of Regulations, title 16, section 1735.6, states in pertinent part:
3	
4	(b) Any equipment used to compound drug products shall be stored, used, and maintained in accordance with manufacturer's specifications.
5	
6	13. California Code of Regulations, title 16, section 1751.4, states in pertinent part:
7	
8	(c) All equipment used in the designation area or cleanroom must be made of a material that can easily be cleaned and disinfected.
9	
10	14. California Code of Regulations, title 16, section 1751.7, states in pertinent part:
11	
12	(b) Each individual involved in the preparation of sterile injectable products must first successfully complete a validation process The validation process shall
13	be carried out in the same manner as normal production, except that an appropriate microbiological growth medium is used in place of the actual product used during
14	sterile preparation. The validation process shall be representative of all types of manipulations, products and batch sizes the individual is expected to prepare. The
15	same personnel, procedures, equipment, and materials must be involved. Completed medium samples must be incubated
16	
17	COST RECOVERY
18	15. Business and Professions Code section 125.3 provides, in pertinent part, that a board
19	may request the administrative law judge to direct a licentiate found to have committed a
20	violation or violations of the licensing act to pay a sum not to exceed the reasonable costs of the
21	investigation and enforcement of the case.
22	BACKGROUND
23	16. On August 20, 2014, the Board conducted an inspection at Respondent's facility
24	located in Birmingham, Alabama. Respondent is an out-of-state pharmacy licensed with both a
25	non-resident pharmacy permit and a non-resident sterile compounding permit.
26	///
27	///
28	///
	4
	(WELLNESS PHARMACY, INC. DBA WELLNESS PHARMACY) ACCUSATION

17. The inspection was conducted by Board inspector P.P.

18. After arriving at Respondent's facility, Pharmacist-In-Charge M.D., assisted
 Inspector P.P. with the investigation by escorting Inspector P.P. through the facility. Upon
 reaching the compounding area of the pharmacy, Inspector P.P. entered the compounding area for
 the purpose of inspection.

19. Upon entering the compounding area, where Respondent conducted high risk sterile 6 drug compounding, Inspector P.P. observed three laminar flow hoods.¹ Inspector P.P. observed 7 Hood #1 to be in good operating condition. Inspector P.P. observed Hood #2 to have cracked 8 glass and rust or some other substance or debris inside the metal track holding the glass. 9 Respondent did not conduct surface testing to determine whether the rust or other substance or 10 debris was causing any problems with unwanted bacterial or fungal growth. Inspector P.P. 11 observed Hood #3 to have a broken light, an abundance of rust throughout the hood, and a dark 12 and slimy appearing substance inside the grates of the hood. 13

- 20. While inside the compounding area, Inspector P.P. observed a chair in front of Hood
 #1 with a damaged seatback. The condition of the chair was such that the inner cushioning of the
 seatback protruded from the chair.
- 17 21. When asked, it was determined that Respondent maintained no records of the
 18 materials compounded under each hood. Thus, if a problem with contamination occurred, it
 19 would be difficult, if not impossible, to narrow down the source of the contamination. When the
 20 master formula for compounded materials was reviewed, it was determined that Respondent's
 21 master formulas failed to identify the equipment used during and for the compounding.

22 22. Process validation is when an individual demonstrates that he or she is familiar with 23 the techniques to compound or mix medication, aseptically. Process validation is required 24 annually unless the pharmacist completes compounding of medications that are classified as 25 "high risk," in which case process validation is required every six months according to United

26

27

28

1

¹ A laminar flow hood is an enclosed work bench where air is drawn through a filter and blown over the work area in a manner designed to prevent contamination of the materials being prepared within the hood.

]	
1	States Pharmacopeia <797>. Respondent represented that Alabama, the state in which
2	Respondent operates, complies with United States Pharmacopeia <797> and therefore,
3	Respondent was required to complete process validation every six months. Respondent's records
4	indicated that Respondent regularly compounded medication in batches of up to 900ml at a time.
5	Thereafter, the compounded medication would be manipulated or divided into smaller dispensing
6	sizes for distribution. The validation process records indicated that Respondent's compounding
7	staff regularly used a smaller quantity than what was actually compounded for production. The
8	records of process validation showed that Respondent's compounding staff conducted process
9	validation with only approximately 85ml when the intended production batch of medication
10	would be 700ml.
11	EDGE CALIGE FOD DISCUDI INF
12	<u>FIRST CAUSE FOR DISCIPLINE</u> (Failure to Record Equipment Used in Compounding)
13	23. Respondent's Non-Resident Pharmacy Permit and Non-Resident Sterile
14	Compounding Permit are subject to disciplinary action under California Code of Regulations, title
15	16, section 1735.2, subdivision (d)(2) in that Respondent did not specify equipment used in
16	compounding as detailed above in Paragraph 21.
17 18	<u>SECOND CAUSE FOR DISCIPLINE</u> (Failure to Maintain Equipment in Good Working Condition)
19	24. Respondent's Non-Resident Pharmacy Permit and Non-Resident Sterile
20	Compounding Permit are subject to disciplinary action under California Code of Regulations, title
21	16, sections 1714 and 1735.6, subdivision (d)(2) in that Respondent conducted compounding of
22	high risk sterile drug compounds in damaged and dirty laminar flow hoods as detailed above in
23	Paragraph 19.
24	THIRD CAUSE FOR DISCIPLINE
25	(Failure to Use Easily Cleaned and Disinfected Equipment in Designated Cleanroom)
26	25. Respondent's Non-Resident Pharmacy Permit and Non-Resident Sterile
27	Compounding Permit are subject to disciplinary action under California Code of Regulations, title
28	16, section 1751.4, subdivision (c) in that Respondent utilized a chair in the sterile compounding
	6
	(WELLNESS PHARMACY, INC. DBA WELLNESS PHARMACY) ACCUSATION

above in Paragraph 20. 3 FOURTH CAUSE FOR DISCIPLINE (Failure to Process Validation Manipulations in Volumes Consistent with Amounts Anticipated to be Prepared) 5 26. Respondent's Non-Resident Pharmacy Permit and Non-Resident Sterile 6 Compounding Permit are subject to disciplinary action under California Code of Regulation 7 16, section 1751.7 in that Respondent conducted process validation in amounts that were no 8 indicative of the high volume batches prepared by the pharmacy as detailed above in Paragr 9 22. 10 PRAYER 11 WHEREFORE, Complainant requests that a hearing be held on the matters herein alled 12 and that following the hearing, the Board of Pharmacy issue a decision: 13 1. Revoking or suspending Non-Resident Pharmacy Permit Number NRP 549, issu 14 Wellness Pharmacy, Inc. dba Wellness Pharmacy; 15 2. Revoking or suspending Non-Resident Sterile Compounding Permit Number N 16 99103, issued to Wellness Pharmacy, Inc. dba Wellness Pharmacy; 17 3. Ordering Wellness Pharmacy, Inc. dba Wellness Pharmacy to pay the Board of Pharmacy the reasonable costs of the investigation and enforcement of this case, pursuant to 18 Business and Professions Code section 125.3; 4. Taking such other and further action as deemed necessary and proper.			
FOURTH CAUSE FOR DISCIPLINE (Failure to Process Validation Manipulations in Volumes Consistent with Amounts Anticipated to be Prepared) 5 26. Respondent's Non-Resident Pharmacy Permit and Non-Resident Sterile 6 Compounding Permit are subject to disciplinary action under California Code of Regulation 7 16, section 1751.7 in that Respondent conducted process validation in amounts that were no 8 indicative of the high volume batches prepared by the pharmacy as detailed above in Parager 9 22. 10 PRAYER 11 WHEREFORE, Complainant requests that a hearing be held on the matters herein alle 12 and that following the hearing, the Board of Pharmacy issue a decision: 13 1. Revoking or suspending Non-Resident Pharmacy Permit Number NRP 549, issu 14 Wellness Pharmacy, Inc. dba Wellness Pharmacy 15 2. Revoking or suspending Non-Resident Sterile Compounding Permit Number N 16 99103, issued to Wellness Pharmacy, Inc. dba Wellness Pharmacy to pay the Board of 18 Pharmacy the reasonable costs of the investigation and enforcement of this case, pursuant to 19 Business and Professions Code section 125.3; 20 4. Taking such other and further action as deemed necessary and proper. 21 Zite of California <td< th=""><th>1</th><th>room that was in such a condition that it could not be easily cleaned and disinfected as detailed</th></td<>	1	room that was in such a condition that it could not be easily cleaned and disinfected as detailed	
4 (Failure to Process Validation Manipulations in Volumes Consistent with Amounts Anticipated to be Prepared) 5 26. Respondent's Non-Resident Pharmacy Permit and Non-Resident Sterile 6 Compounding Permit are subject to disciplinary action under California Code of Regulation 7 16, section 1751.7 in that Respondent conducted process validation in amounts that were no indicative of the high volume batches prepared by the pharmacy as detailed above in Paragre 9 22. 10 PRAYER 11 WHEREFORE, Complainant requests that a hearing be held on the matters herein alle and that following the hearing, the Board of Pharmacy issue a decision: 13 1. Revoking or suspending Non-Resident Pharmacy Permit Number NRP 549, issu 14 Wellness Pharmacy, Inc. dba Wellness Pharmacy 15 2. Revoking or suspending Non-Resident Sterile Compounding Permit Number N 16 99103, issued to Wellness Pharmacy, Inc. dba Wellness Pharmacy; 17 3. Ordering Wellness Pharmacy, Inc. dba Wellness Pharmacy to pay the Board of 18 Pharmacy the reasonable costs of the investigation and enforcement of this case, pursuant to 19 Business and Professions Code section 125.3; 20 4. Taking such other and further action as deemed necessary and proper. 21 VIRGINIA HEROLD 22 <th>2</th> <th>above in Paragraph 20.</th>	2	above in Paragraph 20.	
4 Consistent with Amounts Anticipated to be Prepared) 5 26. Respondent's Non-Resident Pharmacy Permit and Non-Resident Sterile 6 Compounding Permit are subject to disciplinary action under California Code of Regulation 7 16, section 1751.7 in that Respondent conducted process validation in amounts that were no 8 indicative of the high volume batches prepared by the pharmacy as detailed above in Paragre 9 22. 10 PRAYER 11 WHEREFORE, Complainant requests that a hearing be held on the matters herein alled and that following the hearing, the Board of Pharmacy issue a decision: 13 1. Revoking or suspending Non-Resident Pharmacy Permit Number NRP 549, issue 14 Wellness Pharmacy, Inc. dba Wellness Pharmacy 15 2. Revoking or suspending Non-Resident Sterile Compounding Permit Number N 16 99103, issued to Wellness Pharmacy, Inc. dba Wellness Pharmacy to pay the Board of 18 Pharmacy the reasonable costs of the investigation and enforcement of this case, pursuant to 19 Business and Professions Code section 125.3; 20 4. Taking such other and further action as deemed necessary and proper. 21 22 23 DATED: Slide of California 24 Executive Officer <th>3</th> <th></th>	3		
6 Compounding Permit are subject to disciplinary action under California Code of Regulation 16, section 1751.7 in that Respondent conducted process validation in amounts that were no indicative of the high volume batches prepared by the pharmacy as detailed above in Paragr 9 9 22. 10 PRAYER 11 WHEREFORE, Complainant requests that a hearing be held on the matters herein allor and that following the hearing, the Board of Pharmacy issue a decision: 13 1. 14 Wellness Pharmacy, Inc. dba Wellness Pharmacy Permit Number NRP 549, issu 15 2. 16 99103, issued to Wellness Pharmacy, Inc. dba Wellness Pharmacy; 17 3. Ordering Wellness Pharmacy, Inc. dba Wellness Pharmacy to pay the Board of Pharmacy the reasonable costs of the investigation and enforcement of this case, pursuant to Business and Professions Code section 125.3; 19 DATED: $\mathcal{B}/19/16$ 22 VIRGINIA HEROLD Executive Officer Board of Pharmacy Department of Consumer Affairs State of California <i>Complainant</i>	4		
7 16, section 1751.7 in that Respondent conducted process validation in amounts that were no 8 indicative of the high volume batches prepared by the pharmacy as detailed above in Paragre 9 22. 10 PRAYER 11 WHEREFORE, Complainant requests that a hearing be held on the matters herein alle 12 and that following the hearing, the Board of Pharmacy issue a decision: 13 1. Revoking or suspending Non-Resident Pharmacy Permit Number NRP 549, issu 14 Wellness Pharmacy, Inc. dba Wellness Pharmacy 15 2. Revoking or suspending Non-Resident Sterile Compounding Permit Number N 16 99103, issued to Wellness Pharmacy, Inc. dba Wellness Pharmacy; 17 3. Ordering Wellness Pharmacy, Inc. dba Wellness Pharmacy to pay the Board of 18 Pharmacy the reasonable costs of the investigation and enforcement of this case, pursuant to 19 Business and Professions Code section 125.3; 20 4. Taking such other and further action as deemed necessary and proper. 21 DATED: 21/14/16 22 VIRGINIA HEROLD 23 DATED: 21/19/16 24 VIRGINIA HEROLD 25 Board of Pharmacy 26 Dat	5	26. Respondent's Non-Resident Pharmacy Permit and Non-Resident Sterile	
 indicative of the high volume batches prepared by the pharmacy as detailed above in Paragra 22. PRAYER WHEREFORE, Complainant requests that a hearing be held on the matters herein alle and that following the hearing, the Board of Pharmacy issue a decision: Revoking or suspending Non-Resident Pharmacy Permit Number NRP 549, issue Wellness Pharmacy, Inc. dba Wellness Pharmacy Revoking or suspending Non-Resident Sterile Compounding Permit Number NR 549, issue to Wellness Pharmacy, Inc. dba Wellness Pharmacy; Revoking or suspending Non-Resident Sterile Compounding Permit Number NR 99103, issued to Wellness Pharmacy, Inc. dba Wellness Pharmacy; Ordering Wellness Pharmacy, Inc. dba Wellness Pharmacy to pay the Board of Pharmacy the reasonable costs of the investigation and enforcement of this case, pursuant to Business and Professions Code section 125.3; Taking such other and further action as deemed necessary and proper. DATED: <u>8/19//6</u> <u>WirgGINIA HEROLD</u> Executive Officer Board of Pharmacy Department of Consumer Affairs State of California <i>Complainant</i> 	6	Compounding Permit are subject to disciplinary action under California Code of Regulations, title	
9 22. 10 PRAYER 11 WHEREFORE, Complainant requests that a hearing be held on the matters herein alle 12 and that following the hearing, the Board of Pharmacy issue a decision: 13 1. Revoking or suspending Non-Resident Pharmacy Permit Number NRP 549, issu 14 Wellness Pharmacy, Inc. dba Wellness Pharmacy 15 2. Revoking or suspending Non-Resident Sterile Compounding Permit Number N 16 99103, issued to Wellness Pharmacy, Inc. dba Wellness Pharmacy; 17 3. Ordering Wellness Pharmacy, Inc. dba Wellness Pharmacy to pay the Board of 18 Pharmacy the reasonable costs of the investigation and enforcement of this case, pursuant to 19 Business and Professions Code section 125.3; 20 A. Taking such other and further action as deemed necessary and proper. 21 DATED: Slight/lb 22 VIRGINIA HEROLD 23 DATED: Slight of Pharmacy 24 Department of Consumer Affairs 25 State of California 26 Complainant	7	16, section 1751.7 in that Respondent conducted process validation in amounts that were not	
Image: Prescription of the second state of the investigation and enforcement of this case, pursuant to Business and Professions Code section 125.3; Image: Pharmacy issue is a state of the investigation and enforcement of this case, pursuant to Business and Professions Code section 125.3; Image: Pharmacy issue is a state of California Complainant of Consumer Affairs State of California Complainant Image: Pharmacy issue is a state of California Complainant Image: Pharmacy issue is a state of California Complainant Image: Pharmacy issue is a state of California Complainant Image: Pharmacy issue is a state of California Complainant Image: Pharmacy issue is a state of California Complainant is state of California Complainant Image: Pharmacy is a state of California Complainant is state of California Complainant Image: Pharmacy is a state of California Complainant is state of California Complainant	8	indicative of the high volume batches prepared by the pharmacy as detailed above in Paragraph	
11 WHEREFORE, Complainant requests that a hearing be held on the matters herein alle 12 and that following the hearing, the Board of Pharmacy issue a decision: 13 1. Revoking or suspending Non-Resident Pharmacy Permit Number NRP 549, issue 14 Wellness Pharmacy, Inc. dba Wellness Pharmacy 15 2. Revoking or suspending Non-Resident Sterile Compounding Permit Number Nr 16 99103, issued to Wellness Pharmacy, Inc. dba Wellness Pharmacy; 17 3. Ordering Wellness Pharmacy, Inc. dba Wellness Pharmacy to pay the Board of 18 Pharmacy the reasonable costs of the investigation and enforcement of this case, pursuant to 19 Business and Professions Code section 125.3; 20 4. Taking such other and further action as deemed necessary and proper. 21 DATED: S/19/16 22 Board of Pharmacy 23 DATED: S/19/16 24 VIRGINIA HEROLD 25 Board of Pharmacy 26 Department of Consumer Affairs 27 Consumer Affairs 27 Department of Consumer Affairs	9	22.	
12 and that following the hearing, the Board of Pharmacy issue a decision: 13 1. Revoking or suspending Non-Resident Pharmacy Permit Number NRP 549, issu 14 Wellness Pharmacy, Inc. dba Wellness Pharmacy 15 2. Revoking or suspending Non-Resident Sterile Compounding Permit Number N 16 99103, issued to Wellness Pharmacy, Inc. dba Wellness Pharmacy; 17 3. Ordering Wellness Pharmacy, Inc. dba Wellness Pharmacy to pay the Board of 18 Pharmacy the reasonable costs of the investigation and enforcement of this case, pursuant to 19 Business and Professions Code section 125.3; 20 4. Taking such other and further action as deemed necessary and proper. 21 22 23 DATED: 24 ViRGINIA HEROLD 25 State of California 26 27 27 0.00000000000000000000000000000000000	10	PRAYER	
13 1. Revoking or suspending Non-Resident Pharmacy Permit Number NRP 549, issu 14 Wellness Pharmacy, Inc. dba Wellness Pharmacy 15 2. Revoking or suspending Non-Resident Sterile Compounding Permit Number N 16 99103, issued to Wellness Pharmacy, Inc. dba Wellness Pharmacy; 17 3. Ordering Wellness Pharmacy, Inc. dba Wellness Pharmacy to pay the Board of 18 Pharmacy the reasonable costs of the investigation and enforcement of this case, pursuant to 19 Business and Professions Code section 125.3; 20 4. Taking such other and further action as deemed necessary and proper. 21 22 23 DATED: 24 VIRGINIA HEROLD 25 State of California 26 Complainant	11	WHEREFORE, Complainant requests that a hearing be held on the matters herein alleged,	
14 Wellness Pharmacy, Inc. dba Wellness Pharmacy 15 2. Revoking or suspending Non-Resident Sterile Compounding Permit Number No. 16 99103, issued to Wellness Pharmacy, Inc. dba Wellness Pharmacy; 17 3. Ordering Wellness Pharmacy, Inc. dba Wellness Pharmacy to pay the Board of 18 Pharmacy the reasonable costs of the investigation and enforcement of this case, pursuant to 19 Business and Professions Code section 125.3; 20 4. Taking such other and further action as deemed necessary and proper. 21 DATED: Slipp/I/6 22 WIRGINIA HEROLD 23 DATED: Slipp/I/6 24 VIRGINIA HEROLD 25 State of California 26 Complainant	12	and that following the hearing, the Board of Pharmacy issue a decision:	
 15 2. Revoking or suspending Non-Resident Sterile Compounding Permit Number No. 99103, issued to Wellness Pharmacy, Inc. dba Wellness Pharmacy; 3. Ordering Wellness Pharmacy, Inc. dba Wellness Pharmacy to pay the Board of Pharmacy the reasonable costs of the investigation and enforcement of this case, pursuant to Business and Professions Code section 125.3; 4. Taking such other and further action as deemed necessary and proper. 2. 8/19/16 DATED: 8/19/16 VIRGINIA HEROLD Executive Officer Board of Pharmacy Department of Consumer Affairs State of California Complainant 	13	1. Revoking or suspending Non-Resident Pharmacy Permit Number NRP 549, issued to	
 99103, issued to Wellness Pharmacy, Inc. dba Wellness Pharmacy; 3. Ordering Wellness Pharmacy, Inc. dba Wellness Pharmacy to pay the Board of Pharmacy the reasonable costs of the investigation and enforcement of this case, pursuant to Business and Professions Code section 125.3; 4. Taking such other and further action as deemed necessary and proper. 21 23 DATED: <u>8/19/16</u> <u>Wirginia Herold</u> Virginia Herold Executive Officer Board of Pharmacy Department of Consumer Affairs State of California <i>Complainant</i> 	14	Wellness Pharmacy, Inc. dba Wellness Pharmacy	
17 3. Ordering Wellness Pharmacy, Inc. dba Wellness Pharmacy to pay the Board of 18 Pharmacy the reasonable costs of the investigation and enforcement of this case, pursuant to 19 Business and Professions Code section 125.3; 20 4. Taking such other and further action as deemed necessary and proper. 21 22 23 DATED: 24 VIRGINIA HEROLD 24 VIRGINIA HEROLD 25 Department of Consumer Affairs 26 State of California 27 Complainant	15	2. Revoking or suspending Non-Resident Sterile Compounding Permit Number NSC	
 Pharmacy the reasonable costs of the investigation and enforcement of this case, pursuant to Business and Professions Code section 125.3; 4. Taking such other and further action as deemed necessary and proper. 24 DATED: <u>8/19/16</u> VIRGINIA HEROLD Executive Officer Board of Pharmacy Department of Consumer Affairs State of California <i>Complainant</i> 	16	99103, issued to Wellness Pharmacy, Inc. dba Wellness Pharmacy;	
 Business and Professions Code section 125.3; 4. Taking such other and further action as deemed necessary and proper. 24 DATED: <u>8/19/16</u> <u>Virginia Herold</u> Virginia Herold Executive Officer Board of Pharmacy Department of Consumer Affairs State of California <i>Complainant</i> 	17	3. Ordering Wellness Pharmacy, Inc. dba Wellness Pharmacy to pay the Board of	
 4. Taking such other and further action as deemed necessary and proper. 21 22 23 DATED: <u>8/19/16</u> <i>Viggualut</i> 24 25 26 27 	18	Pharmacy the reasonable costs of the investigation and enforcement of this case, pursuant to	
21 22 23 24 25 26 27 21 21 22 23 24 25 26 27 20 24 25 26 27 20 20 20 20 20 20 20 20 20 20	19	Business and Professions Code section 125.3;	
22 23 24 24 25 26 27 20 22 23 24 25 26 27 20 20 21 22 23 24 25 26 27 26 27 27 20 20 21 21 21 21 21 21 21 21 21 21	20	4. Taking such other and further action as deemed necessary and proper.	
 23 DATED: <u>\$19/16</u> 24 25 26 27 27 	21		
24 VIRGINIA HEROLD 25 Executive Officer 26 Department of Consumer Affairs 27 State of California 27 Complainant		alialie China Xanda	
 Executive Officer Board of Pharmacy Department of Consumer Affairs State of California <i>Complainant</i> 			
 Department of Consumer Affairs State of California <i>Complainant</i> 		Executive Officer	
Complainant		Department of Consumer Affairs	
28 SA2010102008/12518441.000		SA 2016102068/12218441 dog	
	28		
		7 (WELLNESS PHARMACY, INC. DBA WELLNESS PHARMACY) ACCUSATION	